AccessibilityHelp
Dr. Reddy's Laboratories logo

Dr. Reddy's Laboratories(NYSE) RDY

Market Cap$11.00BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2001)+1,444%
5 Year+11%
1 Year-9%
1 Month+7%
Premium Feature
Moneyball Superscore
66/100
$13.81
+4.54%
+0.60Today
Dr. Reddy's Laboratories last closing stock price
MetricPriceDate
Last closeUSD 13.212026-10-23
Dr. Reddy's Laboratories stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.07%USD 13.072026-10-16
1 month+6.62%USD 12.392026-09-23
3 month+12.04%USD 11.792026-07-24
Year to date-5.24%USD 13.942025-12-31
1 year-9%USD 14.522025-10-23
3 year+0.82%USD 13.102023-10-24
5 year+11.4%USD 11.862021-10-22
Since inception+1,444.13%USD 0.862001-04-11

Dr. Reddy's Laboratories Financials at a Glance

Market Cap

$11.00BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

₹331.38B

Net Income (TTM)

₹28.03B

EPS (TTM)

$0.36

P/E Ratio

29.68

Dividend

$0.08

Beta (Volatility)

0.42 (Low)

Price

$13.81

Volume

991,322.961

Open

$13.60

Previous Close

$13.21

Daily Range

$13.60 - $13.85

52-Week Range

$11.36 - $15.67

Estimated Earnings Date

Jan 22, 2027

RDY News

featured-transcript-logo-template.jpg

Dr. Reddy's Laboratories: 3 Key Takeaways for Long-Term Investors

The Motley Fool TeamOct 25, 2026
Person browsing cosmetics section at store

Can You Buy Accent Microcell Stock (ACCENTMIC) in 2026?

Lyle DalyOct 20, 2026
A hand writing the words EMERGING MARKETS.

What Is an Emerging Market Economy?

Anders BylundSep 14, 2025
GettyImages-1132119369

2 Top Global Value Stocks to Buy Now

Zhiyuan SunJul 8, 2021
pharmaceutical worker wearing protective gear holds pills in hand

Why Is No One Talking About Dr. Reddy's Stock?

James HalleyMay 11, 2021
GettyImages-1141354730

Bristol-Myers Squibb Cuts Deal, Delaying Threat to Top-Selling Revlimid

Todd CampbellSep 17, 2020
GettyImages-185955499

Is Dr. Reddy's Laboratories a Buy?

Zhiyuan SunMay 10, 2020
093 legal settlement

Will a $48 Billion Global Settlement End U.S. Opioid Crisis Lawsuits?

Maxx ChatskoOct 23, 2019
Page 1

RDY: Motley Fool Moneyball Superscore

66

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited is a global pharmaceutical company based in Hyderabad, India, specializing in the manufacturing and marketing of a wide range of pharmaceutical products. The company operates through various segments, including Global Generics, Pharmaceutical Services and Active Ingredients, Proprietary Products, and Others, addressing diverse therapeutic areas.

Products and Services
  • Manufactures prescription and over-the-counter pharmaceutical products
  • Produces active pharmaceutical ingredients and custom APIs
  • Researches unique pharmaceutical formulations and oncology treatments
Growth Outlook
  • Revenue of INR 81.18 billion in Q1 2026 shows strong demand
  • Net income increased to INR 4.44 billion in Q1 2026
  • Partnerships in oncology and biologics enhance growth potential
Financial Highlights
  • Trailing twelve-month revenue of INR 327.73 billion
  • Net profit margin of 9.99% indicates solid profitability
  • Operating cash flow of INR 14.63 billion in Q1 2026 reflects strong cash generation
Dr. Reddy's Laboratories Limited has established itself as a key player in the pharmaceutical industry, with a diverse portfolio that caters to various therapeutic needs. The company's focus on research and development, particularly in oncology and biologics, positions it well for future growth. Recent financial performance highlights a robust revenue stream and profitability, making it an attractive option for potential investors. The company's strategic partnerships further enhance its market presence and growth prospects, indicating a promising outlook in the competitive pharmaceutical landscape.
AI Generated • Oct 22, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

27,527

CEO

Erez Israeli, MBA

Website

www.drreddys.com

Headquarters

Hyderabad, TS 500034, IN

RDY Financials

Key Financial Metrics (TTM)

Gross Margin

49.49%

Operating Margin

8.98%

Net Income Margin

8.48%

Return on Equity

7.37%

Return on Capital

10.97%

Return on Assets

4.87%

Earnings Yield

3.37%

Dividend Yield

0.63%

Payout Ratio

23.81%

Stock Overview

Market Cap

$11.00BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

832.95M

Volume

991.32K

Avg. Volume

2.89M

Financials (TTM)

Gross Profit

₹163.93B

Operating Income

₹29.56B

EBITDA

₹53.96B

Operating Cash Flow

₹30.11B

Capital Expenditure

-₹18.10B

Free Cash Flow

₹12.01B

Cash & ST Invst.

₹76.58B

Total Debt

₹72.60B

Dr. Reddy's Laboratories Performance Analysis

Dr. Reddy's Laboratories annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31INR 3,060,162,5016.3%
20242024-03-31INR 3,372,211,74410.2%
20252025-03-31INR 3,850,357,35514.2%
20262026-03-31INR 3,801,955,901-1.3%
Dr. Reddy's Laboratories sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-12-31-0.9%
Q42026-03-31-12.5%
Q12026-06-306.4%
Q22026-09-306.7%
Dr. Reddy's Laboratories annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31INR 0.6777.3%
20242024-03-31INR 0.8119.7%
20252025-03-31INR 0.80-0.7%
20262026-03-31INR 0.58-27.4%
Dr. Reddy's Laboratories sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-12-31-15.8%
Q42026-03-31-81.5%
Q12026-06-3099.6%
Q22026-09-30114.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2027YOY CHG

Revenue

₹86.59B

-1.7%

Gross Profit

₹45.14B

-6.2%

Gross Margin

52.13%

N/A

Market Cap

$11.00BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$399.73K

N/A

Employees

27,527

N/A

Net Income

₹9.24B

-35.7%

EBITDA

₹17.14B

-29.5%

Quarterly Fundamentals

Name
Q2 2027YOY CHG

Total Cash

₹76.58B

+9.7%

Total Debt

₹72.60B

+24.0%

Accounts Receivable

₹101.84B

-15.7%

Inventory

₹81.54B

+7.5%

Long Term Debt

₹11.74B

+0.9%

Short Term Debt

₹60.86B

+29.8%

Return on Assets

4.87%

N/A

Return on Invested Capital

7.06%

N/A

Free Cash Flow

₹2.31B

-57.6%

Operating Cash Flow

₹4.69B

-69.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AMRXAmneal Pharmaceuticals, Inc.
$21.10+3.53%
BHCBausch Health Companies Inc.
$6.41-0.47%
ANIPANI Pharmaceuticals, Inc.
$73.49+1.21%
AMPHAmphastar Pharmaceuticals, Inc.
$25.57+1.69%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$12.09-20.25%
EWZiShares - iShares Msci Brazil ETF
$32.66-23.32%
ITUBItaú Unibanco
$7.34-24.15%
CLROClearOne
$5.37+65.23%

Questions About RDY

What is the current price of Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories is trading at $13.82 per share.

What is the 52-week range for Dr. Reddy's Laboratories?

Over the past 52 weeks, Dr. Reddy's Laboratories has traded between $11.36 and $15.67.

How much debt does Dr. Reddy's Laboratories have?

As of the most recent reporting period, Dr. Reddy's Laboratories reported total debt of ₹754.35M.

How much cash does Dr. Reddy's Laboratories have on hand?

Dr. Reddy's Laboratories reported ₹138.73M in cash and cash equivalents in its most recent financial results.

What is Dr. Reddy's Laboratories’s dividend yield?

Dr. Reddy's Laboratories currently has a dividend yield of 0.63%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services